Similar articles

• Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

  Pradeep C-, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y. Pradeep C-, et al. Oncogene. 2025 May;44(17):1207. doi: 10.1038/s41388-025-03362-8. Oncogene. 2025. PMID: 40216970 No abstract available.
• Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

  Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B. Decensi A, et al. Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17. Cancer Prev Res (Phila). 2011. PMID: 21685235 Clinical Trial.
• Premalignant and in situ breast disease: biology and clinical implications.

  Arpino G, Laucirica R, Elledge RM. Arpino G, et al. Ann Intern Med. 2005 Sep 20;143(6):446-57. doi: 10.7326/0003-4819-143-6-200509200-00009. Ann Intern Med. 2005. PMID: 16172443
• Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.

  Zachariah NN, Basu A, Gautam N, Ramamoorthi G, Kodumudi KN, Kumar NB, Loftus L, Czerniecki BJ. Zachariah NN, et al. Front Immunol. 2021 Nov 24;12:786286. doi: 10.3389/fimmu.2021.786286. eCollection 2021. Front Immunol. 2021. PMID: 34899753 Free PMC article.
• Molecular and biologic markers of premalignant lesions of human breast.

  Krishnamurthy S, Sneige N. Krishnamurthy S, et al. Adv Anat Pathol. 2002 May;9(3):185-97. doi: 10.1097/00125480-200205000-00002. Adv Anat Pathol. 2002. PMID: 11981114 Review.